EUVIMEDEUVIMED entdecken
Crossref

Regorafenib inhibits growth, survival and angiogenesis in nasopharyngeal carcinoma and is synergistic with Mcl-1 inhibitor

Jiangping Li, Qingquan Hua iD

Journal of Pharmacy and Pharmacology · 2023

DOI: 10.1093/jpp/rgad034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2023. Verfasst von Jiangping Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology & Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, People's Republic of China. Hauptthemen laut MEDLINE: Nasopharyngeal Neoplasms, Antineoplastic Agents. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Wu Jieping Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Regorafenib is an oral multi-kinase inhibitor approved for various metastatic/advanced cancers, and has been investigated in clinical trials in many other tumour entities. The purpose of this study was to evaluate the therapeutic potential of regorafenib for nasopharyngeal carcinoma (NPC).

Methods

Cellular proliferation, survival, apoptosis and colony formation assays were performed and combination index was determined. NPC xenograft tumour models were established. In vitro and In vivo angiogenesis assays were performed. Key findings Regorafenib is effective against a panel of NPC cell lines regardless of cellular origin and genetic profiling while sparing normal nasal epithelial cells. The predominant inhibitory effects of regorafenib in NPC are anchorage-dependent and anchorage-independent growth rather than survival. Apart from tumour cells, regorafenib potently inhibits angiogenesis. Mechanistically, regorafenib inhibits multiple oncogenic pathways including Raf/Erk/Mek and PI3K/Akt/mTOR. Regorafenib decreases Bcl-2 but not Mcl-1 level in NPC cells. The in vitro observations are evident in in vivo NPC xenograft mouse model. The combination of Mcl-1 inhibitor with regorafenib is synergistic in inhibiting NPC growth without causing systemic toxicity in mice.

Conclusions

Our findings also support further clinical investigation of regorafenib and Mcl-1 inhibitor for NPC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal NeoplasmsAntineoplastic AgentsHumansAnimalsMiceNasopharyngeal CarcinomaPhosphatidylinositol 3-KinasesCell Line, TumorCell ProliferationXenograft Model Antitumor AssaysApoptosisPhenylurea CompoundsPyridines

Stichwörter der Autor:innen

Mcl-1 inhibitorNPCangiogenesisregorafenib

Substanzen

Phosphatidylinositol 3-KinasesAntineoplastic AgentsregorafenibPhenylurea CompoundsPyridines

Autor:innen und Institutionen

  • Department of Otolaryngology & Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, People's Republic of China.
  • Department of Otolaryngology & Head and Neck Surgery, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei 441021, People's Republic of China.

ORCID-Profile: Qingquan Hua

Förderung

  • Wu Jieping Medical Foundation

Zitieren

APA

Li, J., & Hua, Q. (2023). Regorafenib inhibits growth, survival and angiogenesis in nasopharyngeal carcinoma and is synergistic with Mcl-1 inhibitor. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgad034

Vancouver

Li J, Hua Q. Regorafenib inhibits growth, survival and angiogenesis in nasopharyngeal carcinoma and is synergistic with Mcl-1 inhibitor. Journal of Pharmacy and Pharmacology. 2023. doi:10.1093/jpp/rgad034

BibTeX
@article{Li2023,
  author = {Li, Jiangping and Hua, Qingquan},
  title = {Regorafenib inhibits growth, survival and angiogenesis in nasopharyngeal carcinoma and is synergistic with Mcl-1 inhibitor},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2023},
  doi = {10.1093/jpp/rgad034}
}
Kostenlos starten →